



Handling Oxygenation Targets in the Intensive Care Unit

Information for health care professionals

Your department enrolls patients in
the HOT-ICU trial

The HOT-ICU trial compares two separate targets of partial pressure of arterial oxygen (PaO_2) in guiding oxygen administration in critically ill patients

The HOT-ICU trial enrolls 2928 patients admitted to European intensive care units (ICUs)

The HOT-ICU trial is supported by public and private foundations

The HOT-ICU trial is approved by all relevant authorities

Queries? Please contact:

hot-icu@cric.nu

Olav Lilleholt Schjørring, coordinating investigator
Phone: +45 9766 1921

Bodil Steen Rasmussen, sponsor
Phone: +45 9766 1864

Do you need help?
Call the HOT-ICU hotline
+45 2118 2543
Available 24/7
OR
hot-icu@cric.nu



Clinicians' role in HOT-ICU

stating inclusion of the patient to the HOT-ICU trial as well as the allocated oxygenation target.

During the ICU stay

The allocated oxygenation target of a PaO_2 of 8.0 kPa or 12.0 kPa should be upheld for as long as the patient is admitted to the ICU (maximum 90 days). If the patient is discharged and readmitted to the ICU, please continue the allocation.

Screening

When a patient is admitted to the ICU please evaluate the patient for inclusion in the trial. If all inclusion criteria are fulfilled, the ICU physician on duty is requested to screen the patient at www.cric.nu/hot-icu. Even though one or more exclusion criteria are met, we kindly ask you to complete the screening procedure.

Randomisation (by physician)

Remember to obtain consent according to your national regulations before randomisation (if required).

Complete the screening procedure. If the patient fulfils the inclusion criteria and no exclusion criteria are met, you will get the opportunity to randomise the patient. Click 'Perform randomisation'. A window with the allocated oxygenation target will appear (PaO_2 of 8.0 kPa or 12.0 kPa).

Randomisation complete

NIN: D333333333
Name: John Doe
Participant ID: DK01008

Participant randomised to:
8 kPa (60 mmHg)

Background

The trial manuals and other relevant documents are available at www.cric.nu/hot-icu (trial documents)

Queries?

If you have any queries do not hesitate to contact coordinating investigator Olav Lillehol Schjørring. See contact information at the back of this leaflet.

Print or write down the oxygenation target. If you wish to confirm the allocated oxygenation target you can find it at the bottom of the screening form or in an email, which is sent to you upon randomisation, the email is sent to the email address you used for login.

Adjust the FiO_2 to achieve the allocated oxygenation target immediately after completed randomisation.
Prescribe the allocated oxygenation target in the patient's ICU chart and write a note in the patient's medical journal

Methods

In total 2928 patients admitted to European ICUs will be randomised to a PaO_2 target of

- either • 8.0 kPa
- or • 12.0 kPa

Throughout the duration of the ICU stay including readmissions up until maximally 90 days after randomisation.

Results

At the end of the trial we will calculate the 90-day mortality and days alive without life-support, days alive and out of hospital, and the incidences of new episode of cardiac ischaemia, gastrointestinal ischaemia, ischaemic stroke, and shock within the 90-day period.

Funding

The trial has a budget at 10.4 million Danish kroner (1.4 million Euro) and is funded by public and private foundations (Innovation Fund Denmark, Obel Family Foundation and Danish Society of Anaesthesia and Intensive Care Medicine)

The full protocol is available at

www.cric.nu/hot-icu

Manuals

Information about HOT-ICU

Acutely ill adults with hypoxaemic respiratory failure admitted to the ICU are at risk of life-threatening hypoxia and thus oxygen is administered. However, the evidence on the optimal level of oxygenation is of low quality and quality with no firm evidence for benefit or harm. Importantly, liberal use of supplementary oxygen may increase the number of serious adverse events including death.
The aim of the HOT-ICU trial is to assess benefits and harms of two targets of PaO_2 in guiding the oxygen administration in acutely ill adult ICU patients with hypoxaemic respiratory failure, hereby improving the evidence of optimal targets of oxygenation within the ICU.